NUC 1031

Drug Profile

NUC 1031

Alternative Names: Acelarin; CPF-31; Gemzar ProTide - NuCana; MTL-007; NUC-1031

Latest Information Update: 08 Aug 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cardiff University
  • Developer Imperial College of Science, Technology and Medicine; NuCana
  • Class Antineoplastics
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Pancreatic cancer
  • Phase II Ovarian cancer
  • Phase I/II Solid tumours
  • Phase I Biliary cancer; Bladder cancer; Non-small cell lung cancer

Most Recent Events

  • 16 Dec 2016 Biomarkers information updated
  • 22 Jul 2016 Phase-I clinical trials in Ovarian cancer (Combination therapy) (IV) (NuCana pipeline, July 2016)
  • 22 Jul 2016 Phase-II clinical trials in Ovarian cancer (Monotherapy) (IV) (NuCana pipeline, July 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top